"Rethinking Prostate Cancer Screening: Balancing Benefits and Risks"
A study has revealed that PSA tests for prostate cancer may fail to detect some aggressive forms of the disease, leading to potential misdiagnosis and delayed treatment. Researchers found that the commonly used PSA test missed over 15% of aggressive prostate cancers, particularly in men with high PSA levels. This highlights the limitations of the test and the need for improved methods to accurately detect and diagnose aggressive prostate cancer.